glp 1 agonist dpp 4 inhibitor DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner Clinical Use of DPP-4 Inhibitors
Description
The rapidness of weight loss on GLP-1 therapy can have visible costs
What results can I expect from Retatrutide
While GLP-1s represent a major clinical advancement, the broad demand for a high-priced medicine creates a level of financial strain that is difficult to absorb at scale
Couzin-Frankel 6 Sept 2023
The foundation's Canadian survey found that 51 percent of employers now cover GLP-1 drugs for diabetes alone, down from 56 percent in 2025 and 66 percent in 2024
Effects on gastric emptying are significant and appear to lessen with long-term use, possibly due to tachyphylaxis of vagal nerve activation
